Israel-based oral drug delivery systems developer Oramed Pharmaceuticals has received two additional patent approvals in Japan and Canada for its platform protein oral delivery (POD) technology.
The two patents are entitled 'Methods and Compositions for Oral Administrations of Proteins.'
Oramed's POD technology addresses the obstacles to the oral administration of small protein (peptide) molecules, in addition to protecting and improving protein delivery and absorption via the digestive system and into the bloodstream.
The POD technology can also be used to develop oral alternatives for a number of injectable therapies.
Oramed, which develops oral delivery solutions for drugs and vaccines currently delivered via injection, is currently looking to develop the treatment of diabetes through its product ORMD-0801.
The company is currently advancing with clinical trials of ORMD-0801, an orally ingestible insulin capsule, for the treatment of type 1 diabetes.
